Roundview Capital LLC Sells 561 Shares of Johnson & Johnson (NYSE:JNJ)

Roundview Capital LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 56,922 shares of the company’s stock after selling 561 shares during the quarter. Johnson & Johnson accounts for approximately 1.3% of Roundview Capital LLC’s portfolio, making the stock its 16th largest holding. Roundview Capital LLC’s holdings in Johnson & Johnson were worth $8,475,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Newfound Research LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $28,000. Islay Capital Management LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth approximately $42,000. FAI Wealth Management grew its position in shares of Johnson & Johnson by 45.9% in the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after buying an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC grew its position in shares of Johnson & Johnson by 160.0% in the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after buying an additional 200 shares during the last quarter. Finally, HWG Holdings LP purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $49,000. Hedge funds and other institutional investors own 67.44% of the company’s stock.

Shares of NYSE:JNJ opened at $150.85 on Tuesday. The business has a fifty day moving average price of $145.39 and a 200-day moving average price of $146.58. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The company has a market capitalization of $397.12 billion, a PE ratio of 23.72, a PEG ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.22. The business had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. Johnson & Johnson’s revenue was up 1.7% compared to the same quarter last year. During the same period last year, the business earned $2.12 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.01 dividend. The ex-dividend date of this dividend is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a yield of 2.68%. Johnson & Johnson’s payout ratio is currently 46.54%.

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Several research firms recently weighed in on JNJ. Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $161.00 to $164.00 in a report on Monday, July 20th. Cantor Fitzgerald lifted their target price on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Credit Suisse Group lifted their price objective on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday, October 14th. Finally, Stifel Nicolaus downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Buy” and a consensus target price of $164.93.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: Google Finance Portfolio Tips and Tricks

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.